ArticleActa parasitologica2025
Protective Effect of S-Methylcysteine Against Toxoplasma gondii-Induced Reproductive Toxicity in Female Albino Rats.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToxoplasma gondii (T. gondii) is a zoonotic parasite that causes severe disease, particularly in immunocompromised individuals. Current treatments have significant side effects and are ineffective against the latent stage of the parasite. S-Methylcysteine (SMC), a compound from garlic, has antioxidant and anti-inflammatory properties, but its efficacy against T. gondii is unknown.
objectiveTo evaluate the in vivo effects of SMC on T. gondii infection, focusing on hormonal and histopathological changes and its therapeutic potential. MATERIALS AND
methodsForty-eight adult female albino rats were divided into eight groups of six. Four groups were infected intra-vaginally with 200 T. gondii cysts, while controls received saline. For two months, treatment groups were administered daily doses of SMC (50 mg/kg), Spiramycin (200 mg/kg), or a combination of both via gastric tube. After sacrifice, blood samples were collected for hormonal analysis (estrogen, progesterone, LH, FSH). The ovaries and uterus were excised and histologically examined using hematoxylin and eosin staining for microscopic evaluation.
resultsToxoplasma gondii infection caused significant hormonal disruption and severe uterine and ovarian inflammation. Treatment with either SP or SMC alone partially mitigated these effects. However, the combined SMC and Spiramycin treatment showed the most significant improvement, significantly mitigated hormonal imbalances and promoted substantial tissue recovery.
conclusionS-Methylcysteine shows promising therapeutic potential in ameliorating the hormonal and histopathological damage associated with T. gondii infection, especially when combined with Spiramycin. Future studies, including human clinical trials, are needed to investigate its mechanisms and confirm its safety and effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.